

Acquisition of Shares in Dialysate Manufacturer in Germany (Conversion into Subsidiary)

We are pleased to announce that our consolidated subsidiary Nipro Medical Europe N.V. (Headquarters: Mechelen, Belgium; Representative: Serge Kemps, CEO; hereinafter, “Nipro Medical Europe”) has acquired all issued shares of MTN Neubrandenburg GmbH (hereinafter, “MTN”) to convert it into a consolidated subsidiary.

1. Purpose for acquiring shares

Having a manufacturing base in Neubrandenburg, northern Germany, MTN manufactures and sells dialysate used for artificial dialysis treatment.

Our group has been actively promoting the global expansion of the medical device business and has already established dialysate manufacturing sites in the US, Brazil and Spain. With the acquisition of MTN’s shares, we will strengthen the supply system of dialysate in Europe, especially Germany and Eastern Europe, and increase sales of other products for dialysis treatment, including dialyzers, to promote the establishment of a system for manufacturing and selling products that fully takes into account the perspective of users.

2. Overview of Acquisition of MTN’s shares

- (1) Details of share acquisition: All issued shares of MTN
- (2) Shares acquired from: Irmtraud Steinert
- (3) Date of share acquisition: July 24, 2020
- (4) Overview of the company from which shares were acquired
 - (1) Company name: MTN Neubrandenburg GmbH
 - (2) Representative: Irmtraud Steinert
 - (3) Location: Gustav-Kirchhoff-Straße 2, 17033 Neubrandenburg, Germany
 - (4) Established: May 2007
 - (5) Main business: Manufacture and sales of dialysate
 - (6) Capital: 100,000 euros

4. Impact on business results

The impact of share acquisition on the business results for the current fiscal year (ending March 2021) is expected to be immaterial.